The Myeloma UK Clinical Trial Network (CTN) has achieved another significant milestone with data from the MUK six trial published in the latest issue of Lancet Haematology. MUK six, a Phase I/II multicentre open label trial aimed to determine the safety and both the optimum and maximum dose of panobinostat when used in combination with once-weekly Velcade,…
High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges. Muchtar E et al. Leuk Lymphoma. 2016 Oct 13:1-14. [Epub ahead of print]. Is the revised International staging system for myeloma valid in a real world population? Walker I et al. Br J Haematol. 2016 Oct 13. doi: 10.1111/bjh.14341. [Epub ahead of print]. Progress in Myeloma – A Monoclonal Breakthrough. Rajkumar SV et al. N Engl J Med. 2016 Oct 6;375(14):1390-1392. Next-generation multiple…
A population-based study of the impact of dialysis on mortality in multiple myeloma. Evison F et al. Br J Haematol. 2016 Oct 21. doi: 10.1111/bjh.14394. [Epub ahead of print]. Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study. Yin QS et al. Med Sci Monit. 2016 Oct 20;22:3835-3842. Effect of Systemic Therapies…
Management of gynaecologic plasmacytoma: A review article. Feldman AM et al. J Obstet Gynaecol. 2016 Oct 19:1-6. [Epub ahead of print]. Current treatments for renal failure due to multiple myeloma. Gavriatopoulou M et al. Expert Opin Pharmacother. 2016 Nov;17(16):2165-2177. Epub 2016 Sep 27. Comparative Confocal and Histopathological Study of Corneal Changes in Multiple Myeloma. Micali A et al. Cornea. 2016 Oct 5. [Epub ahead of print].…
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Mateos MV et al. Ann Hematol. 2016 Oct 14. [Epub ahead of print]. Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for…
Advances in understanding prognosis in myeloma. Smith D et al. Br J Haematol. 2016 Sep 8. doi: 10.1111/bjh.14304. [Epub ahead of print]. Stem Cell Transplantation In Multiple Myeloma. Offidani M et al. Curr Cancer Drug Targets. 2016 Sep 19. [Epub ahead of print]. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modernmultiple myeloma therapy. Voorhees PM et…
Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis. Kobayashi T et al. Ann Hematol. 2016 Sep 6. [Epub ahead of print]. Mid-term outcomes after radiofrequency-targeted vertebral augmentation in the treatment of myeloma associated vertebral fractures. Ali T et al. Technol Health Care. 2016 Sep 14;24(5):745-51. doi: 10.3233/THC-161222. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile…
Pathological Fracture In Odontoid Process In Multiple Myeloma. Demirci U et al. Turk J Haematol. 2016 Sep 23. doi: 10.4274/tjh.2016.0020. [Epub ahead of print]. Pinpointing a Factor in Myeloma Bone Disease. [No authors listed]. Cancer Discov. 2016 Sep 22. [Epub ahead of print]. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Wanchoo R et al. Clin J Am Soc Nephrol. 2016 Sep 21. pii:…
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Garderet L et al. Haematologica. 2016 Sep 9. pii: haematol.2016.150334. [Epub ahead of print]. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Biran N et al. Blood Cancer…